SemBioSys Genetics has reported preclinical results of plant-produced insulin from the company's proprietary Stratosome Biologics System. The study results will be published in the Plant Biotechnology Journal. The study demonstrates bio-equivalence of purified insulin from Arabidopsis seeds when compared with commercial insulin products in an animal model.
The proof-of-concept study was performed using transgenic Arabidopsis thaliana, the company's plant model system, to determine the feasibility of expressing and recovering biologically active insulin. Using the Stratosome Biologics System, recombinant human insulin was expressed and accumulated in transgenic seed. Insulin tolerance tests demonstrated that the plant-produced insulin was equivalent to commercial sources of human insulin.